- Home
- FCAP vs CRGX Comparison
FCAP vs CRGX Comparison
Compare FCAP & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCAP
- CRGX
- Stock Information
- Founded
- FCAP 1891
- CRGX 2021
- Country
- FCAP United States
- CRGX United States
- Employees
- FCAP N/A
- CRGX N/A
- Industry
- FCAP Savings Institutions
- CRGX
- Sector
- FCAP Finance
- CRGX
- Exchange
- FCAP Nasdaq
- CRGX Nasdaq
- Market Cap
- FCAP 161.2M
- CRGX 190.0M
- IPO Year
- FCAP 1999
- CRGX 2023
- Fundamental
- Price
- FCAP $43.48
- CRGX $4.27
- Analyst Decision
- FCAP
- CRGX Hold
- Analyst Count
- FCAP 0
- CRGX 7
- Target Price
- FCAP N/A
- CRGX $4.67
- AVG Volume (30 Days)
- FCAP 6.7K
- CRGX 647.1K
- Earning Date
- FCAP 07-25-2025
- CRGX 08-11-2025
- Dividend Yield
- FCAP 2.63%
- CRGX N/A
- EPS Growth
- FCAP 2.61
- CRGX N/A
- EPS
- FCAP 3.65
- CRGX N/A
- Revenue
- FCAP $42,869,000.00
- CRGX N/A
- Revenue This Year
- FCAP N/A
- CRGX $58.18
- Revenue Next Year
- FCAP N/A
- CRGX N/A
- P/E Ratio
- FCAP $11.89
- CRGX N/A
- Revenue Growth
- FCAP 6.35
- CRGX N/A
- 52 Week Low
- FCAP $27.71
- CRGX $3.00
- 52 Week High
- FCAP $53.85
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- FCAP 38.73
- CRGX 45.02
- Support Level
- FCAP $43.54
- CRGX $4.33
- Resistance Level
- FCAP $47.55
- CRGX $4.48
- Average True Range (ATR)
- FCAP 1.79
- CRGX 0.19
- MACD
- FCAP -0.44
- CRGX -0.02
- Stochastic Oscillator
- FCAP 15.52
- CRGX 21.14
About FCAP First Capital Inc.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.